Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: A randomized assessor-blind controlled trial

Archives of Dermatology

Volumn 142, Issue 12, 2006, Pages 1575-1579

  Firooz, Alireza ^a   Khamesipour, Ali ^a   Ghoorchi, Mohammad H ^c   Nassiri Kashani, Mansour ^a   Eskandari, S Ebrahim ^a   Khatami, Alireza ^a   Hooshmand, Badakhshan ^b   Gorouhi, Farzam ^a   Rashighi Firoozabadi, Mehdi ^a   Dowlati, Yahya ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; MEGLUMINE ANTIMONATE; PLACEBO;

ADOLESCENT; ADULT; ARTICLE; BURNING SENSATION; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDEMIC DISEASE; FEMALE; HEALTH CENTER; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN LEISHMANIASIS; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 33845710461     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.142.12.1575     Document Type: Article

References (18)

1. Leishmaniasis. In: Tropical Disease Research Progress 1995-96: Thirteenth Programme Report. Geneva, Switzerland: World Health Organization; 1997.
2. Dowlati Y. Cutaneous leishmaniasis: clinical aspect. Clin Dermatol. 1996;14:425-431.
3. Dowlati Y. Treatment of cutaneous leishmaniasis (Old World). Clin Dermatol. 1996;14:513-517.
4. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis. 1997;24:684-703.
5. Buates S, Matlashewski G. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J Infect Dis. 1999;179:1485-1494.
6. Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol. 2000;43(pt 2):S6-S11.
7. Alexander J, Bryson K. T helper (h)1/Th2 and Leishmania: paradox rather than paradigm. Immunol Lett. 2005;99:17-23.
8. Edwards L. Imiquimod in clinical practice. J Am Acad Dermatol. 2000;43(pt 2):S12-S17.
9. Eedy DJ. Imiquimod: a potential role in dermatology? Br J Dermatol. 2002;147:1-6.
10. Imiquimod Prescribing Information. St Paul, Minn: 3M Pharmaceuticals; 2002.
11. Arevalo I, Ward B, Miller R, et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis. 2001;33:1847-1851.
12. Miranda-Verástegui C, Llanos-Cuentas A, Arevalo I, Ward BJ, Matlashewski G. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clin Infect Dis. 2005;40:1395-1403.
13. Herwaldt BL. Leishmaniasis. Lancet. 1999;354:1191-1199.
14. Seeberger J, Dauoud S, Pammer J. Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod. Int J Dermatol. 2003;42:576-579.
15. Crawford R, Holmes D, Meymandi S. Comparative study of the efficacy of combined imiquimod 5% cream and intralesional meglumine antimoniate versus imiquimod 5% cream and intralesional meglumine antimoniate alone for the treatment of cutaneous leishmaniasis [abstract]. J Am Acad Dermatol. 2005;52(suppl 1):S118.
16. Harms G, Chehade AK, Douba M, et al. A randomized trial comparing a pentavalent antimonial drug and recombinant interferon-gamma in the local treatment of cutaneous leishmaniasis. Trans R Soc Trop Med Hyg. 1991;85:214-216.
17. Shani-Adir A, Kamil S, Rozenman D, et al. Leishmania tropica in northern Israel: a clinical overview of an emerging focus. J Am Acad Dermatol. 2005;53:810-815.
18. Hadighi R, Mohebali M, Boucher P, et al. Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug resistant Leishmania tropica parasites. PLoS Med. 2006;3:e162.